Postoperative CCRT With Docetaxel vs Cisplatin in High Risk HNSCC
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized,controled, phase III, open label study of postoperative concurrent
chemoradiotherapy with Docetaxel versus Cisplatinum for high-risk squamous cell carcinoma of
the head and neck(HNSCC).The primary purpose of this study is to evaluate the efficacy and
safety of concurrent chemoradiotherapy with docetaxel in HNSCC patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University